OLD Category: signatures

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

• Färkkilä A et al.,

The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression

• Li Z et al.,

The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression☆

• Li Z et al.,

Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies

• Filipovic A et al.,

Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity

• Horn LA et al.,

Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer

• Kim SY et al.,

T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer

• Obradovic A, Dallos MC, Zahurak ML...De Marzo AM, Antonarakis ES, Drake CG

Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation

• Giannini R et al.,

The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice

• Ly D, Dongol A, Cuthbertson P...Watson D, Yerbury JJ, Sluyter R

The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1(G93A) mice

• Ly D et al.,

Isolation and mutational assessment of pancreatic cancer extracellular vesicles using a microfluidic platform

• Kamyabi N et al.,

A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection

• Wolfe AR et al.,